Mereo BioPharma (MREO) Gains from Sales and Divestitures (2020 - 2024)
Historic Gains from Sales and Divestitures for Mereo BioPharma (MREO) over the last 3 years, with Q4 2024 value amounting to $1.3 million.
- Mereo BioPharma's Gains from Sales and Divestitures rose 16689.34% to $1.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.3 million, marking a year-over-year increase of 16689.34%. This contributed to the annual value of $1.3 million for FY2024, which is 16689.34% up from last year.
- Latest data reveals that Mereo BioPharma reported Gains from Sales and Divestitures of $1.3 million as of Q4 2024, which was up 16689.34% from $1.3 million recorded in Q3 2024.
- Mereo BioPharma's 5-year Gains from Sales and Divestitures high stood at $1.3 million for Q3 2024, and its period low was -$65809.9 during Q2 2020.
- In the last 3 years, Mereo BioPharma's Gains from Sales and Divestitures had a median value of $652135.0 in 2023 and averaged $676223.9.
- Data for Mereo BioPharma's Gains from Sales and Divestitures shows a peak YoY increase of 16689.34% (in 2024) and a maximum YoY decrease of 16689.34% (in 2024) over the last 5 years.
- Over the past 3 years, Mereo BioPharma's Gains from Sales and Divestitures (Quarter) stood at -$65809.9 in 2020, then soared by 861.86% to $501380.0 in 2023, then surged by 166.89% to $1.3 million in 2024.
- Its Gains from Sales and Divestitures was $1.3 million in Q4 2024, compared to $1.3 million in Q3 2024 and $802890.0 in Q2 2024.